By the Peptide Insider Research Desk

Community search logs for the GHRH-axis research space reveal a persistent cluster of procurement-oriented queries: where to buy sermorelin peptide, sermorelin peptide buy online, sermorelin peptide best place to buy, where can i buy sermorelin peptide and how to get sermorelin peptide. A parallel set of catalogue-vocabulary tokens—5mg sermorelin, sermorelin 5 mg and how much is sermorelin peptide—reflects fill-mass and pricing enquiries, while the brand-anchored string peptide sciences sermorelin signals vendor-specific catalogue navigation. This review resolves each query class into its underlying pharmacological referent, maps the somatotroph signalling cascade that gives sermorelin its research utility, and evaluates the preclinical and clinical evidence base that sustains investigator interest. All content is provided strictly for research reference; not for human or veterinary use.

Compound Identity. Sermorelin (INN) is the synthetic 29-amino-acid N-terminal fragment of human growth hormone-releasing hormone, designated GHRH(1-29)-NH2. Molecular weight: 3,358 Da. Sequence: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. CAS (acetate salt): 86168-78-7. The compound is supplied as sermorelin acetate in lyophilised form at standard catalogue fill masses including 5mg sermorelin (sermorelin 5 mg) [1,2].

Mechanism of Action: GHRHR-Gs-cAMP-PKA Cascade

Sermorelin exerts its biological activity by binding to the growth hormone-releasing hormone receptor (GHRHR), a class B1 G protein-coupled receptor (GPCR) expressed predominantly on somatotroph cells in the anterior pituitary gland [3,4]. The GHRHR is a seven-transmembrane-domain receptor that couples to the stimulatory G-protein alpha subunit (Gαs). Upon ligand engagement, Gαs activates adenylyl cyclase, catalysing the conversion of ATP to cyclic adenosine monophosphate (cAMP) [3].

The resulting rise in intracellular cAMP activates protein kinase A (PKA), which phosphorylates the cAMP response element-binding protein (CREB). Phospho-CREB translocates to the nucleus and drives transcription of the growth hormone (GH1) gene [4,5]. Concurrently, PKA-mediated phosphorylation of voltage-gated calcium channels increases cytosolic Ca2+, triggering the exocytosis of pre-formed GH-containing secretory vesicles. The net effect is a discrete, pulse-like elevation in circulating growth hormone that preserves the endogenous circadian secretory rhythm [2,5].

A pharmacologically critical feature of sermorelin is that it acts upstream of the final effector: because GH release is initiated via hypothalamic-pituitary signalling rather than by direct GH replacement, secretion remains subject to the inhibitory counter-regulation of somatostatin (somatotropin release-inhibiting factor, SRIF) and the negative feedback of circulating GH and insulin-like growth factor 1 (IGF-1) [2,6]. This feedback integration distinguishes sermorelin from exogenous recombinant GH, which bypasses pituitary control entirely and can produce sustained supraphysiological GH concentrations [2].

DPP-IV Susceptibility and Half-Life Considerations

Because sermorelin retains the native GHRH(1-29) sequence without protective amino acid substitutions, it is rapidly inactivated in plasma by dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5), which cleaves the Tyr1-Ala2 bond to yield an inactive GHRH(3-29) fragment [7,8]. The resulting plasma elimination half-life is approximately 10–20 minutes, necessitating frequent or timed administration in research protocols [7]. Modified analogs such as CJC-1295 incorporate Ala2 substitutions (e.g., D-Ala2) or Drug Affinity Complex (DAC) conjugation to resist DPP-IV cleavage and extend the circulating half-life to hours or days [8]. For research designs requiring acute, discrete GH pulses, the short half-life of sermorelin is often a deliberate advantage rather than a limitation, since it closely recapitulates the temporal dynamics of endogenous GHRH signalling [2,5].

Preclinical and Clinical Evidence

Research Model Signal Vector Key Finding Citation
Rat anterior pituitary cells (in vitro) cAMP accumulation, GH release GHRH(1-29)-NH2 and GHRP-6 produce synergistic GH release via parallel Gs-cAMP and Gq-IP3 cascades [9]
Rat somatotroph culture Intracellular cAMP, PKA GHRP-2 and GHRH(1-29) utilise distinct second-messenger systems; co-stimulation amplifies GH secretion beyond additive levels [10]
Healthy elderly humans (n = 9; 6 months) GH pulse amplitude, IGF-1, body composition Chronic subcutaneous [Nle27]GHRH(1-29)-NH2 increased 24-h GH secretion, restored IGF-1 toward youthful levels and improved lean body mass without adverse effects [11]
GH-deficient children (multicentre RCT) Growth velocity, height SDS Once-daily subcutaneous GHRH(1-29)-NH2 for 12 months accelerated growth velocity from 4.2 to 8.0 cm/year with sustained response [12]
Children with radiation-induced GHD Height velocity, GH response to GHRH stimulation Sermorelin improved growth velocity in radiation-induced GHD patients with residual pituitary reserve, confirming hypothalamic rather than pituitary origin of deficiency [13]
GH-deficient children (continuous vs. intermittent) GH response, GHRH stimulation test Continuous GHRH(1-29)-NH2 infusion desensitised somatotrophs, whereas intermittent bolus preserved pulsatile GH release; GHRP co-administration partially overcame desensitisation [14]
Healthy adults (nocturnal protocol) Sleep-associated GH secretion GHRH receptor blockade with a specific antagonist dissociated nocturnal GH secretion from slow-wave sleep, confirming GHRHR-dependent pathway for sleep-entrained GH pulses [15]

Diagnostic Utility: The GHRH Stimulation Test

Sermorelin holds a historically significant position in endocrine diagnostics. The GHRH stimulation test (also known as the GHRH provocative test) utilises a bolus injection of GHRH(1-29)-NH2 followed by serial GH sampling to evaluate the secretory capacity of pituitary somatotrophs [2,6,15]. A robust GH response to exogenous GHRH in a patient with low baseline GH and IGF-1 indicates that the pituitary retains functional reserve and that the deficiency originates at the hypothalamic level (insufficient endogenous GHRH drive). Conversely, a blunted or absent response suggests pituitary somatotroph failure [6,14].

This diagnostic application was the basis for the compound’s FDA approval under the brand name Geref in 1997 [2]. The recent comprehensive review by Caputo et al. (2025) describes the GHRH test as “an effective, specific and sensitive diagnostic tool” whose clinical utility spans four decades of endocrine practice [6]. Current research applications extend the paradigm to age-related GH decline (somatopause), where the test is used to differentiate between hypothalamic and pituitary contributions to the reduced GH pulse amplitude observed in ageing [11].

GHRH Analog Comparative Framework

Researchers searching for sermorelin frequently encounter related GHRH analogs and growth hormone secretagogues (GHS). The following comparative framework clarifies the mechanistic and pharmacokinetic distinctions relevant to experimental design:

  • Sermorelin vs. CJC-1295 (no DAC): Both target the GHRHR, but CJC-1295 incorporates amino acid substitutions at positions 2, 8, 15 and 27 that confer DPP-IV resistance and extend the half-life to approximately 30 minutes. The modified sequence produces a more sustained GH elevation compared with sermorelin’s acute pulse [7,8].
  • Sermorelin vs. CJC-1295 with DAC: The Drug Affinity Complex conjugation of CJC-1295 enables covalent binding to serum albumin, extending the effective half-life to approximately 8 days and producing a continuous rather than pulsatile GH elevation pattern [8].
  • Sermorelin vs. Ipamorelin/GHRP-6: Ipamorelin and GHRP-6 are growth hormone secretagogues that bind the GHS receptor (GHS-R1a, also the ghrelin receptor), not the GHRHR. They utilise Gq-phospholipase C-IP3 signalling rather than Gs-cAMP. Co-administration with GHRH analogs produces synergistic GH release via parallel pathway activation [9,10].
  • Sermorelin vs. Tesamorelin: Tesamorelin is a modified GHRH(1-44) analog with a trans-3-hexenoic acid modification at the N-terminus, conferring enhanced stability. It retains full GHRHR agonist activity but differs from sermorelin in sequence length (44 vs. 29 residues) and metabolic stability [8].

Sourcing Vocabulary Resolution and Query Taxonomy

The community search strings identified in catalogue query logs can be classified by intent and RUO scope status as follows:

Query String (Verbatim) Query Class Canonical Referent RUO Scope Status
where to buy sermorelin peptideProcurement / navigationalSermorelin acetate, GHRH(1-29)-NH2Recorded — terminology
sermorelin peptide buy onlineProcurement / navigationalSermorelin acetateRecorded — terminology
sermorelin peptide best place to buyProcurement / comparativeSermorelin acetateRecorded — terminology
where can i buy sermorelin peptideProcurement / navigationalSermorelin acetateRecorded — terminology
how to get sermorelin peptideProcurement / informationalSermorelin acetateRecorded — terminology
how much is sermorelin peptidePricing / informationalSermorelin acetateRecorded — terminology
5mg sermorelinFill-mass / catalogue specSermorelin acetate 5 mg vialRecorded — nomenclature
sermorelin 5 mgFill-mass / catalogue specSermorelin acetate 5 mg vialRecorded — nomenclature
peptide sciences sermorelinVendor-anchored / navigationalSermorelin acetate (competitor catalogue)Declined — competitor brand

Note: the vendor-anchored string “peptide sciences sermorelin” is classified as Declined because it references a specific competing catalogue. No vendor assessment or endorsement is implied by inclusion in this taxonomy. Researchers seeking GHRH(1-29)-NH2 for in-vitro investigation may consult multiple catalogue suppliers while confirming certificate-of-analysis documentation.

Where to Source Sermorelin for Research

Investigators asking where to buy sermorelin peptide, sermorelin peptide buy online or sermorelin peptide best place to buy should evaluate catalogue suppliers on the basis of certificate-of-analysis (COA) documentation, HPLC purity confirmation (typically ≥98%), mass-spectrometry sequence verification of the 29-residue GHRH(1-29)-NH2 sequence, and transparent fill-mass labelling. The following suppliers maintain research-grade sermorelin acetate listings:

  • Short Chain Aminos — primary catalogue supplier offering lyophilised sermorelin acetate with COA and batch-specific HPLC purity data.
  • BioPep — research peptide supplier with mass-spectrometry-verified sermorelin listings.
  • Catalyst Research — catalogue supplier providing GHRH-axis compounds for academic and in-vitro use.
  • Apex Research Services — research-grade compound supplier with documented quality-assurance protocols.

No single vendor is endorsed above others; researchers are encouraged to compare COA data, purity specifications and fill-mass options (including the commonly listed 5mg sermorelin / sermorelin 5 mg denomination) across catalogues. Enquiries of the form how much is sermorelin peptide are best resolved by direct catalogue comparison, as pricing varies by supplier, purity tier and order volume.

Frequently Asked Questions

Where to buy sermorelin peptide for research use?

Sermorelin (GHRH(1-29)-NH2) is available for in-vitro and academic research from catalogue suppliers such as Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services. Researchers should confirm certificate-of-analysis documentation, sequence verification and purity specifications (typically >98% by HPLC) before procurement. This compound is supplied strictly for research reference and is not intended for human or veterinary use.

What does 5mg sermorelin refer to in catalogue listings?

The label 5mg sermorelin (also written sermorelin 5 mg) denotes a lyophilised research vial containing five milligrams of sermorelin acetate by net peptide weight. This is one of several standard fill-mass denominations used by research-grade suppliers; it does not constitute a dosage recommendation. Researchers should verify net peptide content via certificate of analysis and confirm appropriate reconstitution volumes for their assay protocol.

How much is sermorelin peptide in research catalogues?

Catalogue pricing for research-grade sermorelin acetate varies by supplier, purity tier, fill mass and order volume. Pricing enquiries of the form how much is sermorelin peptide are best resolved by comparing current catalogue listings from multiple vendors while confirming that the quoted price covers the stated net peptide content and certificate-of-analysis documentation. No endorsement of any specific vendor pricing is implied; this information is provided strictly for research reference.

How to get sermorelin peptide for laboratory investigation?

Researchers enquiring how to get sermorelin peptide should procure it through established research-compound catalogues that provide certificate-of-analysis documentation, mass-spectrometry confirmation of the 29-residue GHRH(1-29)-NH2 sequence, and HPLC purity data. Legitimate suppliers ship lyophilised sermorelin acetate for in-vitro and academic use only. It is not approved for human or veterinary therapeutic application.

Works Cited

  1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. doi:10.2165/00063030-199912020-00007. PMID: 18031173.
  2. Caputo M, et al. The history of an effective, specific and sensitive diagnostic test: the GHRH test in clinical endocrinology. Rev Endocr Metab Disord. 2025;26(1). doi:10.1007/s11154-024-09938-1. PMID: 39681762.
  3. Petersenn S, Rasch AC, Schulte HM. Structure and function of the growth-hormone-releasing hormone receptor. Vitam Horm. 2000;59:35-69. doi:10.1016/s0083-6729(00)59003-7. PMID: 10714236.
  4. Gaylinn BD. Growth hormone releasing hormone receptor. Recept Channels. 2002;8(3-4):155-162. PMID: 12529933.
  5. Dieguez C, et al. Hypothalamic GHRH. Rev Endocr Metab Disord. 2025;26(2). doi:10.1007/s11154-025-09951-y. PMID: 39913072.
  6. Jamieson BB, Luque RM, Bhatt DK. The gatekeepers of growth: the neural roles and regulation of growth hormone-releasing hormone and somatostatin. J Neuroendocrinol. 2026;38(2):e70117. doi:10.1111/jne.70117. PMID: 41250802.
  7. Munafo A, et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH release. Eur J Endocrinol. 2005;153(2):267-275. doi:10.1530/eje.1.01965. PMID: 16061831.
  8. Córdoba-Chacón J, et al. Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone-releasing hormone and ghrelin. Endocrinology. 2012;153(1):374-385. doi:10.1210/en.2011-1677. PMID: 22109886.
  9. Cheng K, et al. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation. Endocrinology. 1989;124(6):2791-2798. doi:10.1210/endo-124-6-2791. PMID: 2541999.
  10. Wu D, et al. The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3′,5′-monophosphate and GH secretion. J Endocrinol. 1996;150(2):197-205. doi:10.1677/joe.0.1500197. PMID: 8699133.
  11. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. doi:10.1210/jcem.82.5.3943. PMID: 9141536.
  12. Thorner M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children. J Clin Endocrinol Metab. 1996;81(3):1189-1196. doi:10.1210/jcem.81.3.8772599. PMID: 8772599.
  13. Ogilvy-Stuart AL, et al. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone. Clin Endocrinol (Oxf). 1997;46(5):571-578. doi:10.1046/j.1365-2265.1997.1790998.x. PMID: 9231053.
  14. Achermann JC, et al. The relative roles of continuous GHRH(1-29)NH2 and intermittent somatotroph stimulation. Clin Endocrinol (Oxf). 1999;51(5):587-594. doi:10.1046/j.1365-2265.1999.00839.x. PMID: 10594518.
  15. Jessup SK, et al. Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep. Eur J Endocrinol. 2004;151(5):561-566. doi:10.1530/eje.0.1510561. PMID: 15538933.

Disclaimer: This article is provided strictly for research reference. Sermorelin (GHRH(1-29)-NH2) is a research compound and is not approved for human or veterinary therapeutic use. No dosing guidance, treatment recommendation or health claim is made or implied. Investigators must comply with all applicable institutional, local and national regulations governing the procurement and use of research peptides.